Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.58 |
| ▸ | CBR1 | P16152 | 1/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28360593 | 0.88 | TTR (0.50) | TTRHPGDSLC6A2SLC6A3MAPT | |
| SCHEMBL4875968 | 0.88 | ALDH1A1 (0.49) | TTRHPGDSLC6A2SLC6A3MAPT | |
| SCHEMBL3652668 | 0.86 | MAPT (0.63) | TTRHPGDSLC6A2SLC6A3MAPT | |
| SCHEMBL7668913 | 0.86 | CYP3A4 (0.52) | TTRHPGDSLC6A2SLC6A3MAPT | |
| SCHEMBL7186092 | 0.85 | TTR (0.75) | TTRHPGDSLC6A2SLC6A3MAPT | |
| SCHEMBL3049386 | 0.85 | ALDH1A1 (0.54) | TTRHPGDSLC6A2SLC6A3MAPT | |
| SCHEMBL641111 | 0.85 | CYP2C9 (0.56) | TTRHPGDSLC6A2SLC6A3MAPT | |
| Hydrochloric Acid SCHEMBL11346813 | 0.84 | MAPT (0.67) | TTRHPGDSLC6A2SLC6A3MAPT | |
| SCHEMBL11453570 | 0.84 | TTR (0.58) | TTRHPGDSLC6A2SLC6A3MAPT | |
| SCHEMBL9658647 | 0.84 | SLC6A3 (0.59) | TTRHPGDSLC6A2SLC6A3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890547-A2 | CONTROL OF PARASITES IN ANIMALS BY N-[(PHENYLOXY)PHENYL]-1,1,1-TRIFLUOROMETHANESULFONAMIDE AND N-[(PHENYLSULFANYL)PHENYL]-1,1,1-TRIFLUOROMETHANESULFONAMIDE DERIVATIVES | Schering-Plough Ltd. (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006135648-A2 | CONTROL OF PARASITES IN ANIMALS BY N-[(PHENYLOXY)PHENYL]-1,1,1-TRIFLUOROMETHANESULFONAMIDE AND N-[(PHENYLSULFANYL)PHENYL]-1,1,1-TRIFLUOROMETHANESULFONAMIDE DERIVATIVES | SCHERING-PLOUGH LTD. (CH) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281695-A1 | Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281695-A1 | Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives | ELANE, CTRL, PIGO | TTR 975/4885HPGD 3154/4885SLC6A2 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.